Study to evaluate real-world safety, effectiveness and appropriate use of Micatrio® Combination Tablets treatment in patients with hypertension
Non-interventional study based on newly collected data. The study will consist of a baseline visit and follow-up visits at Week 4, 8, 12, 24, 36 and 52 for patients who have newly initiated Micatrio® Combination Tablets. The patients will be followed up until discontinuation of Micatrio® Combination Tablets treatment or the end of study. All patients administrated Micatrio® Combination Tablets after the launch at the sites contracted with the sponsor will be registered.
Study Type
OBSERVATIONAL
Enrollment
676
Drug
Nippon Boehringer Ingelheim Co., Ltd
Tokyo, Japan
Frequency of Patients With Any Suspected Adverse Drug Reactions
An Adverse drug reaction (ADR) is defined as an AE for which either the investigator or the sponsor (or both) assess the causal relationship to Micatrio Combination Tablets as related. The frequency of patients with any suspected ADR is presented as total number of participants with an ADR reported.
Time frame: from first intake of Micatrio combination tablet until last intake +1 day (week 52)
Change From Baseline in Clinic Diastolic Blood Pressure at Week 52
Change from baseline in clinic diastolic blood pressure (DBP) millimeters of mercury \[mmHg\] at Week 52
Time frame: At baseline and week 52
Change From Baseline in Clinic Systolic Blood Pressure at Week 52
Change from baseline in clinic systolic blood pressure (SBP) millimeters of mercury at Week 52
Time frame: At baseline and week 52
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.